FNBP4

Summary

FNBP4 (formin binding protein 4, HGNC:19752) is a protein-coding gene on chromosome 11p11.2, encoding Formin-binding protein 4 (Q8N3X1). It is a selective cancer dependency (DepMap: 60.3% of cell lines).

This gene encodes a protein containing two tryptophan-rich WW domains that binds the proline-rich formin homology 1 domains of formin family proteins, suggesting a role in the regulation of cytoskeletal dynamics during cell division and migration. It also binds intersectin family proteins suggesting a role in the maintenance of membrane curvature at sites of nascent vesicle formation. Naturally occurring mutations in this gene are associated with Waardenburg anophthalmia syndrome.

Source: NCBI Gene 23360 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 153 total
• Cancer dependency (DepMap): dependent in 60.3% of screened cell lines
• MANE Select transcript: NM_015308

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19752
Approved symbol	FNBP4
Name	formin binding protein 4
Location	11p11.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1014
Ensembl gene	ENSG00000109920
Ensembl biotype	protein_coding
OMIM	615265
Entrez	23360

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 11 protein_coding_CDS_not_defined, 5 protein_coding, 3 retained_intron

ENST00000263773, ENST00000524696, ENST00000525316, ENST00000525792, ENST00000526109, ENST00000527894, ENST00000528388, ENST00000529156, ENST00000530207, ENST00000531394, ENST00000532646, ENST00000533707, ENST00000534003, ENST00000540172, ENST00000542975, ENST00000544590, ENST00000883715, ENST00000917808, ENST00000961496

RefSeq mRNA: 2 — MANE Select: NM_015308 NM_001318339, NM_015308

CCDS: CCDS41644

Canonical transcript exons

ENST00000263773 — 17 exons

Exon	Start	End
ENSE00000839356	47724468	47724778
ENSE00002182692	47716494	47717512
ENSE00002266360	47767069	47767341
ENSE00003467965	47722976	47723316
ENSE00003481122	47719929	47720086
ENSE00003492569	47754528	47754664
ENSE00003535697	47731374	47731561
ENSE00003538299	47724028	47724172
ENSE00003555480	47743953	47744163
ENSE00003561014	47765270	47765362
ENSE00003566860	47732537	47732670
ENSE00003570308	47751143	47751290
ENSE00003572507	47750916	47751036
ENSE00003591368	47752916	47753102
ENSE00003622600	47746056	47746394
ENSE00003653923	47736616	47736740
ENSE00003665313	47734025	47734129

Expression profiles

Bgee: expression breadth ubiquitous, 207 present calls, max score 98.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 56.9597 / max 898.3696, expressed in 1826 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119669	48.9848	1826
119668	4.3530	1624
119673	1.0772	463
119670	0.9878	484
119671	0.7607	376
119672	0.5594	266
119674	0.2368	95

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	98.37	gold quality
mucosa of stomach	UBERON:0001199	98.34	gold quality
calcaneal tendon	UBERON:0003701	98.33	gold quality
left ovary	UBERON:0002119	98.27	gold quality
body of uterus	UBERON:0009853	98.22	gold quality
right ovary	UBERON:0002118	98.21	gold quality
endocervix	UBERON:0000458	98.18	gold quality
body of pancreas	UBERON:0001150	98.15	gold quality
right uterine tube	UBERON:0001302	98.11	gold quality
left lobe of thyroid gland	UBERON:0001120	98.01	gold quality
right lobe of thyroid gland	UBERON:0001119	97.96	gold quality
nerve	UBERON:0001021	97.94	gold quality
tibial nerve	UBERON:0001323	97.94	gold quality
skin of leg	UBERON:0001511	97.83	gold quality
vermiform appendix	UBERON:0001154	97.76	gold quality
ectocervix	UBERON:0012249	97.74	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.68	gold quality
cerebellar hemisphere	UBERON:0002245	97.67	gold quality
skin of abdomen	UBERON:0001416	97.66	gold quality
left uterine tube	UBERON:0001303	97.58	gold quality
cerebellar cortex	UBERON:0002129	97.54	gold quality
adrenal tissue	UBERON:0018303	97.54	gold quality
ventricular zone	UBERON:0003053	97.50	gold quality
small intestine Peyer’s patch	UBERON:0003454	97.50	gold quality
minor salivary gland	UBERON:0001830	97.47	gold quality
granulocyte	CL:0000094	97.41	gold quality
right lung	UBERON:0002167	97.40	gold quality
rectum	UBERON:0001052	97.34	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.18	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.18	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.95

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

121 targeting FNBP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-539-5P	99.93	70.30	2855

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 60.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• A c.683C>T (p.Thr228Met) mutation in FNBP4 was found as a primary candidate to microphthalmia with limb anomalies (PMID:23703728)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	fnbp4	ENSDARG00000051800
mus_musculus	Fnbp4	ENSMUSG00000008200
rattus_norvegicus	Fnbp4	ENSRNOG00000007241
drosophila_melanogaster	Frl	FBGN0267795
caenorhabditis_elegans		WBGENE00018976
caenorhabditis_elegans		WBGENE00019030
caenorhabditis_elegans	sydn-1	WBGENE00021473
caenorhabditis_elegans		WBGENE00021698

Paralogs (18): DAAM1 (ENSG00000100592), DIAPH1 (ENSG00000131504), FHOD3 (ENSG00000134775), FHOD1 (ENSG00000135723), FHDC1 (ENSG00000137460), DIAPH3 (ENSG00000139734), DAAM2 (ENSG00000146122), DIAPH2 (ENSG00000147202), FMN2 (ENSG00000155816), FMNL2 (ENSG00000157827), FMNL3 (ENSG00000161791), FMNL1 (ENSG00000184922), FAM47A (ENSG00000185448), SHTN1 (ENSG00000187164), FAM47B (ENSG00000189132), FAM47C (ENSG00000198173), INF2 (ENSG00000203485), GRID2IP (ENSG00000215045)

Protein

Protein identifiers

Formin-binding protein 4 — Q8N3X1 (reviewed: Q8N3X1)

Alternative names: Formin-binding protein 30

All UniProt accessions (2): Q8N3X1, F5GXL1

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Binds FMN1. Interacts with the Arg/Gly-rich-flanked Pro-rich of KHDRBS1/SAM68. Arginine methylation in these regions has no effect on this binding.

Tissue specificity. Highly expressed in the eye.

Domain organisation. These WW domains interact with Arg/Gly-rich-flanked Pro-rich domains found in several WW domain-binding proteins (WBPs). The N-terminal WW domain has the greater ligand-binding ability.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N3X1-1	1	yes
Q8N3X1-2	2

RefSeq proteins (2): NP_001305268, NP_056123* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001202	WW_dom	Domain
IPR036020	WW_dom_sf	Homologous_superfamily
IPR053076	WW_domain_protein	Family

Pfam: PF00397

UniProt features (56 total): modified residue 19, compositionally biased region 17, region of interest 6, cross-link 6, sequence variant 3, domain 2, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N3X1-F1	56.84	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (25): 18, 116, 124, 172, 290, 427, 432, 435, 438, 442, 464, 479, 499, 508, 516, 517, 963, 964, 965, 301 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 209 (showing top): MODULE_255, BROWNE_HCMV_INFECTION_8HR_UP, MODULE_317, ONKEN_UVEAL_MELANOMA_UP, FOSTER_TOLERANT_MACROPHAGE_UP, FISCHER_G2_M_CELL_CYCLE, OCT1_03, FISCHER_DREAM_TARGETS, BILBAN_B_CLL_LPL_DN, DELASERNA_MYOD_TARGETS_DN, MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_UP, CHANDRAN_METASTASIS_UP, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, MODULE_69, CHEN_HOXA5_TARGETS_9HR_UP

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1719 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FNBP4	WBP4	O75554	687
FNBP4	GRID2IP	A4D2P6	630
FNBP4	FMNL3	Q8IVF7	604
FNBP4	FMN1	Q68DA7	595
FNBP4	DAAM2	Q86T65	594
FNBP4	FMNL1	O95466	590
FNBP4	DIAPH2	O60879	579
FNBP4	FMNL2	Q96PY5	575
FNBP4	LENG8	Q96PV6	551
FNBP4	NUP160	Q12769	543
FNBP4	DAAM1	Q9Y4D1	543
FNBP4	DIAPH1	O60610	534
FNBP4	PFN4	Q8NHR9	529
FNBP4	PFN3	P60673	526
FNBP4	FHOD1	Q9Y613	524

IntAct

55 interactions, top by confidence:

A	B	Type	Score
FNBP4	PRPF40A	psi-mi:“MI:0914”(association)	0.550
FNBP4	PRPF40A	psi-mi:“MI:0915”(physical association)	0.550
KHDRBS1	FNBP4	psi-mi:“MI:0407”(direct interaction)	0.540
KHDRBS1	FNBP4	psi-mi:“MI:0915”(physical association)	0.540
BAG2	HGS	psi-mi:“MI:0914”(association)	0.530
ZC3H18	AQR	psi-mi:“MI:0914”(association)	0.530
ZC3H18	SRPK2	psi-mi:“MI:0914”(association)	0.530
FNBP4	H2BC21	psi-mi:“MI:0915”(physical association)	0.400
HSCB	FNBP4	psi-mi:“MI:0915”(physical association)	0.370
PLXNA2	FNBP4	psi-mi:“MI:0915”(physical association)	0.370
HTT	FNBP4	psi-mi:“MI:0915”(physical association)	0.370
FNBP4	HTT	psi-mi:“MI:0915”(physical association)	0.370
Psmb4	PSMD14	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
CEP135	MCRIP1	psi-mi:“MI:0914”(association)	0.350
CEP135	WWP2	psi-mi:“MI:0914”(association)	0.350
CEP135	WDR91	psi-mi:“MI:0914”(association)	0.350
RBM39	RPS3A	psi-mi:“MI:0914”(association)	0.350
hspa1a_hspa1b_human-1	SHTN1	psi-mi:“MI:0914”(association)	0.350
BAG1	PSMD11	psi-mi:“MI:0914”(association)	0.350
FGF12	SUPT5H	psi-mi:“MI:0914”(association)	0.350
ARHGAP12	WASL	psi-mi:“MI:0914”(association)	0.350
TGM1	DNM1L	psi-mi:“MI:0914”(association)	0.350
HSPA2	HGS	psi-mi:“MI:0914”(association)	0.350

BioGRID (99): FNBP4 (Affinity Capture-RNA), FNBP4 (Affinity Capture-RNA), FNBP4 (Proximity Label-MS), FNBP4 (Affinity Capture-MS), FNBP4 (Affinity Capture-MS), FNBP4 (Affinity Capture-MS), FNBP4 (Affinity Capture-RNA), FNBP4 (Affinity Capture-RNA), FNBP4 (Affinity Capture-MS), FNBP4 (Affinity Capture-MS), FNBP4 (Affinity Capture-MS), FNBP4 (Proximity Label-MS), FNBP4 (Affinity Capture-MS), FNBP4 (Proximity Label-MS), FNBP4 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTU1, A2AUY4, B7ZS37, D3Z8Y2, D4A4L4, D4A666, E1B7L7, O46385, O60293, O75152, O95425, P0DQW0, Q08AZ1, Q3KQW7, Q3U1C4, Q3UH68, Q3ZC82, Q4G0F8, Q4V9H5, Q5F3Z9, Q5NBX1, Q5REG6, Q5ZJJ1, Q5ZM88, Q61464, Q62394, Q68FE9, Q6NZF1, Q6PJT7, Q6ZQ03, Q6ZU65, Q76L83, Q7TMD5, Q8BHZ4, Q8BJ05, Q8BLG0, Q8BZ32, Q8C9B9, Q8CCJ9, Q8K298

Diamond homologs: Q6ZQ03, Q8N3X1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 68 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Polyadenylation	9	14.9×	1e-06
mRNA Splicing	6	12.4×	6e-04
Processing of Capped Intron-Containing Pre-mRNA	8	12.4×	2e-05
mRNA Splicing - Major Pathway	12	12.4×	5e-08
Dengue Virus-Host Interactions	10	8.6×	2e-05
Metabolism of RNA	8	6.3×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
mRNA splicing, via spliceosome	8	12.2×	6e-05
mRNA processing	9	11.8×	3e-05
RNA splicing	7	10.3×	8e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

153 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	101
Likely benign	9
Benign	11

Top pathogenic / likely-pathogenic (0)

SpliceAI

3023 predictions. Top by Δscore:

Variant	Effect	Δscore
11:47717508:TGCCA:T	acceptor_gain	1.0000
11:47717510:CCA:C	acceptor_gain	1.0000
11:47717511:CA:C	acceptor_gain	1.0000
11:47717511:CAC:C	acceptor_gain	1.0000
11:47717513:C:CC	acceptor_gain	1.0000
11:47719932:A:C	donor_gain	1.0000
11:47719933:CCAG:C	donor_gain	1.0000
11:47720084:TGC:T	acceptor_gain	1.0000
11:47720087:C:CC	acceptor_gain	1.0000
11:47722988:T:TA	donor_gain	1.0000
11:47724171:CT:C	acceptor_gain	1.0000
11:47731368:TCTCA:T	donor_loss	1.0000
11:47731369:CTCAC:C	donor_loss	1.0000
11:47731370:TCA:T	donor_loss	1.0000
11:47731371:CA:C	donor_loss	1.0000
11:47731372:A:AC	donor_gain	1.0000
11:47731373:C:CC	donor_gain	1.0000
11:47731373:C:T	donor_loss	1.0000
11:47731557:GATCC:G	acceptor_gain	1.0000
11:47731558:ATCC:A	acceptor_gain	1.0000
11:47731559:TCC:T	acceptor_gain	1.0000
11:47731560:CC:C	acceptor_gain	1.0000
11:47731560:CCC:C	acceptor_gain	1.0000
11:47731561:CC:C	acceptor_gain	1.0000
11:47731561:CCT:C	acceptor_loss	1.0000
11:47731562:C:CC	acceptor_gain	1.0000
11:47731562:C:T	acceptor_gain	1.0000
11:47731567:T:C	acceptor_gain	1.0000
11:47731567:T:TC	acceptor_gain	1.0000
11:47731901:ATTTC:A	donor_gain	1.0000

AlphaMissense

6595 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:47717464:C:A	W1004C	1.000
11:47717464:C:G	W1004C	1.000
11:47717466:A:G	W1004R	1.000
11:47717466:A:T	W1004R	1.000
11:47720042:C:A	W950C	1.000
11:47720042:C:G	W950C	1.000
11:47720044:A:G	W950R	1.000
11:47720044:A:T	W950R	1.000
11:47731510:C:A	W624C	1.000
11:47731510:C:G	W624C	1.000
11:47731512:A:G	W624R	1.000
11:47731512:A:T	W624R	1.000
11:47731542:A:C	Y614D	1.000
11:47731550:C:G	R611P	1.000
11:47732542:C:A	W605C	1.000
11:47732542:C:G	W605C	1.000
11:47732543:C:G	W605S	1.000
11:47732544:A:G	W605R	1.000
11:47732544:A:T	W605R	1.000
11:47732550:A:G	C603R	1.000
11:47732554:C:A	W601C	1.000
11:47732554:C:G	W601C	1.000
11:47732556:A:G	W601R	1.000
11:47732556:A:T	W601R	1.000
11:47732591:A:G	L589P	1.000
11:47732612:A:G	L582P	1.000
11:47732624:A:G	L578P	1.000
11:47732651:C:G	R569P	1.000
11:47732655:A:G	W568R	1.000
11:47732655:A:T	W568R	1.000

dbSNP variants (sampled 300 via entrez): RS1000167069 (11:47751287 C>A), RS1000200109 (11:47751023 C>A,G,T), RS1000295641 (11:47721483 G>A), RS1000304289 (11:47721463 T>C), RS1000381097 (11:47751442 G>A,C), RS1000430264 (11:47757293 C>T), RS1000452047 (11:47762224 C>T), RS1000511169 (11:47767473 T>C,G), RS1000533234 (11:47735239 T>C), RS1000565854 (11:47728315 T>C), RS1000615497 (11:47739832 G>A), RS1000646850 (11:47739630 A>G), RS1000671141 (11:47720708 A>T), RS1000735414 (11:47763546 G>A,C), RS1000793883 (11:47756629 T>A,C)

Disease associations

OMIM: gene MIM:615265 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST004904_244	Body mass index	1.000000e-09
GCST005232_56	Neuroticism	1.000000e-16
GCST005905_14	Global electrical heterogeneity phenotypes	6.000000e-09
GCST006718_7	Alcohol use disorder (consumption score)	3.000000e-09
GCST006896_9	Free thyroxine concentration	8.000000e-11
GCST006923_11	Loneliness	1.000000e-07
GCST006924_13	Loneliness (MTAG)	1.000000e-08
GCST007559_27	Sleep duration (short sleep)	4.000000e-08
GCST007825_4	Alzheimer’s disease or fasting glucose levels (pleiotropy)	3.000000e-16
GCST007944_2	Medication use (antiglaucoma preparations and miotics)	1.000000e-08
GCST010002_238	Refractive error	2.000000e-14
GCST010136_2	Fruit consumption	5.000000e-09
GCST010703_36	Brain morphology (MOSTest)	8.000000e-09
GCST011369_19	Iron status biomarkers (ferritin levels)	3.000000e-13
GCST90000025_155	Appendicular lean mass	3.000000e-37

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0007660	neuroticism measurement
EFO:0004327	electrocardiography
EFO:0007865	loneliness measurement
EFO:0009944	Antiglaucoma preparations and miotics use measurement
EFO:0008111	diet measurement
EFO:0004346	neuroimaging measurement
EFO:0004459	ferritin measurement
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	4
bisphenol A	decreases expression, decreases methylation, affects cotreatment	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
cobaltous chloride	increases expression	1
manganese chloride	increases abundance, increases expression	1
coumarin	decreases phosphorylation	1
beta-methylcholine	affects expression	1
K 7174	increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	increases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	decreases expression	1
Leflunomide	increases expression	1
Air Pollutants, Occupational	affects expression, increases abundance, increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Cisplatin	decreases expression	1
Demecolcine	increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.